Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab + Axitinib in advanced renal cell carcinoma
NCT07159191Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2025
- Primary completion
- Feb 2027
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
01
Overview
A Phase 2 trial of envafolimab in clear cell renal cell carcinoma (ccRCC), sponsored by Peking Union Medical College Hospital. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
envafolimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07159191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07159191.